Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study *
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Dermatology"
DOI: 10.1111/bjd.19262
Abstract: Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A, a cornerstone cytokine in psoriasis, has shown long‐lasting efficacy and safety in the complete spectrum of psoriasis manifestations. read more here.
Keywords: shows high; efficacy; high sustained; secukinumab shows ... See more keywords